#USA #Telix #Biologics #ImaginAb #Inglewood

Telix Pharmaceuticals Acquires ImaginAb's Innovative Biologics Platform

Inglewood, California - ImaginAb, Inc. recently announced a major agreement where it will sell its innovative pipeline of cutting-edge therapeutic candidates to Telix Pharmaceuticals Limited. This acquisition is seen as a strategic move to bolster the future discovery of next-generation therapeutic assets.

According to the release dated January 22, 2025, the deal includes ImaginAb's proprietary novel biologics technology platform and a specialized protein engineering and research facility. Following the transaction's completion, ImaginAb will direct its efforts towards progressing its flagship imaging solution, CD8 ImmunoPET, which is currently undergoing Phase 2 clinical trials. This imaging candidate has already been licensed by various pharmaceutical and biotech companies aiming to enhance immunotherapy clinical trials, especially within oncology.

Dr. Anna Wu, the founder of ImaginAb, expressed her enthusiasm over the sale, stating, "We are very pleased that Telix recognizes the potential of our novel biological technology platform. This acquisition enables Telix to explore new disease areas utilizing our leading radiotherapeutic technology. It is a significant milestone that validates our unique minibody platform, showcasing the hard work put forth by our scientific team."

ImaginAb will further press on with the development of its CD8 platform, confirming that several prominent pharmaceutical and biotech firms have incorporated its technology into their ongoing immuno-oncology clinical trials. This foundation and support from established entities affirm the potential and reliability of their innovations.

Jefferies LLC and Stifel, Nicolaus & Company, Incorporated acted as financial advisors to ImaginAb throughout the transaction. With ongoing partnerships and a focus on developing its leading imaging candidate, ImaginAb remains dedicated to advancing personalized medicine using its advanced technology.

ImaginAb is not just a pioneering force in imaging technologies, but it operates within the larger framework of global biotechnology companies focused on revolutionizing the field of radiopharmaceuticals. The company's portfolio includes engineered antibodies that deliver specificity without biological inertness, empowering them for effective applications utilizing positron emission tomography (PET) and other imaging advancements that facilitate precise targeting.

The CD8 ImmunoPET technology employs a [89Zr]-labelled minibody, specifically designed to bind the CD8 receptor on human T cells, and is pivotal for quantitative, non-invasive PET imaging of CD8+ cells. By focusing on these key immune system components, the technology allows healthcare professionals to gauge the efficacy of immunotherapies and determine patient outcomes effectively.

In conjunction with this, the Optical PSMA Imaging Agent has emerged as another remarkable advancement. This fluorescent labelled minibody is targeted at the PSMA receptor, primarily present on prostate cancer cells, facilitating quantitative imaging during surgical procedures. This tool not only aids in identifying cancerous tissues but also improves surgical resection outcomes, marking a leap forward in surgical oncology applications.

The strategic direction towards harnessing innovative technology in immunotherapy has garnered acclaim, illustrating a commitment to shaping the future healthcare landscape. As ImaginAb transitions into this new phase of growth, it stands poised to contribute significantly to the realms of cancer diagnostics and treatment efficacy, ensuring that they are well-aligned with emerging medical needs.

For more details about ImaginAb and its pioneering research, check out their dedicated site at www.imaginab.com.